Maitake D-Fraction and Cancer: The Complete Research Review

Maitake D-Fraction & Cancer

1.5–2.2× NK cell activity increase in cancer patients

Maitake D-fraction raised natural killer cell activity by 1.5 to 2.2 times in cancer patients, and tumor markers declined in every patient Kodama examined.

Kodama N et al., Journal of Medicinal Food, 2003

34

postmenopausal breast cancer survivors in the MSKCC phase I/II trial

2022

year of the first RCT testing D-fraction during active chemoradiotherapy

12–28%

improvement in chemo response rates when D-fraction was added to treatment

Kodama N et al., Journal of Medicinal Food, 2003

View as image ↗

In 2022, a randomized controlled trial did something no maitake study had done before: it enrolled patients who were actively undergoing concurrent chemoradiotherapy and tested whether D-fraction could help them through it. Compared to placebo, the D-fraction group experienced significantly fewer adverse events and maintained better quality of life throughout treatment.^[1] That trial by Hu and colleagues is the most recent human data on maitake D-fraction and cancer, and it is data that no major competitor has incorporated.

Maitake D-fraction is not the same as eating maitake mushroom or taking a whole-mushroom supplement. It is a specific polysaccharide extract defined by its beta-1,3 and 1,6-glucan backbone, a structural characteristic that determines how it interacts with immune cells. The evidence behind it accumulates across three decades: from Hiroshi Nanba's original case series work in Japan through the Memorial Sloan Kettering phase I/II trial to the 2022 RCT. Each layer of evidence adds something real, and each comes with important caveats that most summaries omit.

This article traces that full arc. To understand maitake as a mushroom before the cancer research begins, see What Is Maitake Mushroom? The Dancing Mushroom Explained.

What Is Maitake D-Fraction? The Extract Behind the Cancer Research

Maitake D-fraction is a purified polysaccharide extract from Grifola frondosa. Its defining feature is a beta-1,3 and 1,6-glucan backbone, a long branching sugar chain that binds to pattern recognition receptors on macrophages and natural killer cells. Whole maitake mushroom contains this polysaccharide, but in lower, variable concentrations. D-fraction isolates and concentrates it.

Research on maitake D-fraction and cancer focuses specifically on this extract because the glucan concentration needed to engage immune receptors in the way documented in clinical studies is not reliably achievable through whole mushroom consumption alone. D-fraction is an immunomodulator that works by activating macrophages and natural killer cells, not by attacking cancer cells directly. The human evidence includes a phase I/II trial at Memorial Sloan Kettering Cancer Center, a 2022 randomized controlled trial, and a 165-patient case series.

Hiroshi Nanba isolated D-fraction in the 1980s by testing multiple extracted fractions of the maitake polysaccharide for biological activity in animal models. Fraction D showed the strongest effects, and the name stayed. Mayell's 2001 review traced this discovery history and documented the foundational case series data that launched the research program.^[2]

MD-fraction is a subsequent refinement. In MD-fraction, the bound protein that accompanies the glucan in D-fraction is removed, producing a higher-purity glucan. Wu and colleagues clarified this structural distinction in a 2021 review, confirming that both extracts share the same active glucan core but differ in purity and the presence or absence of bound protein.^[3] Supplement labels frequently use the terms interchangeably, which creates confusion when reading the literature. The 165-patient case series, for instance, used MD-fraction not D-fraction. For the full structural and clinical comparison between the two, see Maitake MD-Fraction: The Enhanced Extract for Cancer Research.

For the upstream pharmacology context, including how the beta-glucan in D-fraction reaches immune cells in the body, see The Pharmacology of Grifola frondosa: How Maitake Works.

The 2022 Randomized Trial: D-Fraction During Active Cancer Treatment

Most clinical research on D-fraction has tested patients who already finished cancer treatment. The 2022 trial by Hu and colleagues changed that.

Researchers enrolled patients with laryngeal and pharyngeal cancers who were about to begin concurrent chemoradiotherapy, one of the most immunosuppressive treatment protocols in clinical oncology. Patients were randomized to receive either maitake D-fraction or placebo alongside their standard care throughout the treatment course.^[1]

The D-fraction group had significantly fewer adverse events during treatment. They also maintained better quality of life than the placebo group.

The practical signal from Hu 2022 is this: D-fraction, taken during active chemoradiotherapy, appears to attenuate some of the collateral immune damage that concurrent chemo and radiation produce. Chemoradiotherapy suppresses immune function as a side effect of its intensity. D-fraction, as an immunomodulator, may preserve immune function that would otherwise be lost during treatment.

This was the first RCT to test maitake D-fraction in patients undergoing active cancer treatment. The previous major human studies, including the MSKCC trial, enrolled patients who had already completed treatment. That distinction in study design is the reason the 2022 trial moves the evidence forward: it tests the scenario most relevant to patients currently receiving care.

No major competitor site's content on maitake and cancer incorporates this trial. It was published in the Journal of Ethnopharmacology in 2022 and remains the most recent randomized evidence on D-fraction in cancer patients.

165 Patients, Three Cancer Types: The Foundational Case Series

The response rates most frequently cited in maitake cancer literature come from Kodama and Nanba's 2002 non-randomized case series of 165 patients with Stage II through Stage IV cancers.^[4] Patients received MD-fraction at 100 to 150 mg per day alongside 4 to 6 grams of whole maitake powder. Some patients continued standard chemotherapy as well.

Defined as cancer regression or significant symptom improvement, the response rates by cancer type were:

• Breast cancer: 68.8%
• Lung cancer: 62.5%
• Liver cancer: 58.3%

When MD-fraction was combined with chemotherapy rather than given alone, response rates improved by 12 to 28 percentage points over chemotherapy alone in this dataset.

These numbers require an honest frame. A non-randomized case series has no control group. Without randomization, the effects attributed to D-fraction cannot be isolated from other variables: the patients' baseline health, concurrent treatments, or natural disease variation. What the case series establishes is a consistent signal across three cancer types and a specific protocol: MD-fraction at 100 to 150 mg per day, whole maitake at 4 to 6 grams. That protocol informed the research that followed.

The same research group published a 2003 cohort study tracking natural killer cell activity in cancer patients receiving D-fraction.^[5] Natural killer cells are the immune cells that identify and destroy cancer cells on contact without prior activation. In the patients Kodama measured, NK cell activity increased 1.5 to 2.2 times after D-fraction treatment. Tumor markers, a measure of cancer activity in the blood, declined in every patient examined.

The animal model that preceded this human work showed parallel NK cell dynamics: D-fraction inhibited tumor growth in mice via NK cell activation, establishing the NK cell pathway as the primary antitumor mechanism in that preclinical model.^[6] How the NK activation cascade is triggered at the cellular level, including the macrophage IL-12 step that mediates D-fraction's effect, is covered in How Maitake D-Fraction Activates Anti-Tumor Immunity.

The Dose Finding That Surprised MSKCC Researchers: More Is Not Always Better

The Memorial Sloan Kettering Cancer Center trial, published by Deng and colleagues in 2009, is the highest-quality clinical evidence for the immunological effects of maitake polysaccharide extract in humans.^[7] Thirty-four postmenopausal breast cancer survivors, women who had completed treatment and were disease-free, received the extract twice daily at doses ranging from 0.1 to 5 mg per kilogram of body weight.

The primary outcome was immune function. And the finding was not what researchers expected.

At intermediate doses, immune function was suppressed. At high doses, immune function was enhanced. The relationship between dose and effect was not linear. Researchers described this as a non-monotonic dose response.

More precisely: as dose increased from the lowest tested level, immune markers did not increase proportionally. They declined in the intermediate dose range before recovering and increasing at the highest doses. This is the opposite of what a simple immune stimulant would produce, where more dose reliably means more effect in one direction.

Across all doses tested, no dose-limiting toxicity was observed. The extract was well-tolerated from 0.1 to 5 mg/kg. The safety signal from the MSKCC trial is clear. But the non-monotonic dose response has a significant implication: the dose that produces immune enhancement is not the intuitively obvious one. At intermediate doses, D-fraction can actively suppress the same immune function it enhances at higher doses.

This finding is cited in some systematic reviews but rarely explained in plain language. Competitor content mentions the MSKCC trial as evidence of safety and immunological effects. None explain the non-monotonic pattern or what it means practically. For the breast cancer-specific picture, including what the MSKCC trial's immunological findings mean for breast cancer survivors and the in vitro apoptosis data, see Maitake and Breast Cancer: D-Fraction Clinical Evidence.

Immunomodulator, Not Immune Booster: The Distinction That Changes the Question

Guggenheim and colleagues articulated this distinction precisely in a 2014 review covering all five major medicinal mushrooms in integrative oncology context.^[8] Maitake D-fraction is an immunomodulator. It is not an immune stimulant.

The difference is mechanistic, not semantic. An immune stimulant increases immune function, reliably, in proportion to dose. An immunomodulator regulates immune function: it can increase activity when the immune system is underactive, and suppress activity when it is overactive. The direction depends on context: what the immune system is currently doing, and what dose is administered.

The MSKCC non-monotonic dose finding is not a flaw in the research. It is exactly what you would predict from a true immunomodulator. At intermediate doses, D-fraction's regulatory effect pushes immune function in one direction. At high doses, in the other. This is different in kind from a supplement that "boosts" immunity.

For cancer patients, the distinction shifts the relevant question. Instead of "does D-fraction enhance immune function?", the question becomes: at what dose, in what treatment context, does D-fraction regulate immune function in a way that helps this patient? The 2022 Hu RCT tested one specific answer: during active concurrent chemoradiotherapy, D-fraction preserved immune-related quality of life compared to placebo.

The D-fraction glucan's branching structure is the physical reason for this regulatory capacity. At the specific branch points chemists label beta-1,6, the chain binds to pattern recognition receptors on macrophages, which then initiate a cascade involving interleukin-12 production, NK cell activation, and T cell involvement. That binding activates a regulatory sequence rather than simple amplification. Guggenheim 2014 distinguishes maitake's mechanism from other mushrooms by this specific glucan architecture and the downstream IL-12 pathway it preferentially triggers.^[8]

The 2023 Systematic Review: Where Maitake Fits in the Evidence Hierarchy

A 2023 systematic review examined all medicinal mushroom RCTs in cancer patients and placed maitake alongside turkey tail PSK, reishi polysaccharides, and other extracts in a ranked hierarchy.^[9] Its overall finding: mushroom polysaccharides show consistent immunomodulatory and quality-of-life benefits as adjuvant therapy in cancer patients. Evidence for direct anticancer activity (meaning tumor reduction attributable to the mushroom extract itself) remains insufficient across all mushrooms reviewed.

Within that framework, turkey tail PSK has the broadest RCT base, primarily from Japanese trials spanning several decades. Maitake D-fraction, as of the review, had the MSKCC phase I/II trial and the 2022 RCT in chemoradiotherapy patients. That is a smaller evidence base, but with a specific strength: the 2022 trial is the only mushroom polysaccharide RCT testing quality of life outcomes during active concurrent chemoradiotherapy.

The 2009 systematic review by Ulbricht and colleagues, which represented the state of evidence before the 2022 RCT, reached consistent conclusions: maitake is likely safe, produces measurable immunological effects in humans, and had insufficient evidence for direct anticancer benefit as of 2009.^[10] That review also identified two potential drug interactions that remain relevant: warfarin, because maitake may affect clotting-related parameters; and blood pressure medications, because maitake affects blood pressure in some studies. These interactions were flagged as theoretical rather than confirmed at clinical doses, but the caution is noted.

Camilleri and colleagues' 2024 comprehensive review confirmed D-fraction as maitake's primary anti-cancer bioactive, with growing scientific interest in combination approaches: pairing D-fraction with conventional treatment rather than using it as a standalone intervention.^[11] This framing is consistent with both the 2022 RCT design and the case series data, which found stronger responses when D-fraction was combined with chemotherapy than when it was given alone.

Wong and colleagues' 2020 review evaluated mushroom extracts in breast cancer research using a structured three-tier evidence hierarchy: cell culture, then animal models, then clinical trials.^[12] Maitake D-fraction appeared across all three tiers. That breadth of consistent evidence, from lab to animal to human, is not true of all mushrooms reviewed. In the overall picture, maitake D-fraction is in a different category from extracts with only in vitro data: it has preclinical consistency and a clinical signal, even if the clinical evidence is limited to two human studies.

The honest summary of three decades of research: one phase I/II trial, one RCT, and consistent preclinical evidence. That is more than most integrative oncology interventions have, and less than would be needed to make definitive claims about anticancer benefit. The evidence supports D-fraction as a candidate for adjuvant immunological support, particularly during immunosuppressive treatment. It does not establish D-fraction as a cancer treatment, and no published study has claimed it does.

For a direct comparison of maitake D-fraction against turkey tail PSK, reishi polysaccharides, and other mushroom extracts in the cancer context, see Maitake D-Fraction vs. Other Mushroom Cancer Extracts. For the epidemiological question of whether regular mushroom consumption relates to cancer risk in the general population, see Daily Mushroom Consumption and Cancer Risk Reduction. And for how reishi polysaccharides compare as a cancer adjunct in clinical terms, the Cochrane review data is discussed in Ganoderma lucidum as a Cancer Adjunct: Clinical Evidence.

The Bottom Line

Three decades of research on maitake D-fraction and cancer have produced a consistent pattern: the extract modulates immune function in ways that may support patients undergoing treatment, with the 2022 RCT in chemoradiotherapy patients as the strongest clinical signal to date. The MSKCC phase I/II trial's non-monotonic dose finding (intermediate doses suppress immune function while high doses enhance it) is the most practically important and least-explained data point in the clinical literature. Two systematic reviews characterize the overall evidence as promising for adjuvant immunological support but insufficient for direct anticancer claims.

Frequently Asked Questions

What is maitake D-fraction?

Maitake D-fraction is a purified polysaccharide extract from the maitake mushroom (Grifola frondosa), defined by its beta-1,3 and 1,6-glucan backbone, which binds to receptors on macrophages and natural killer cells to modulate immune function. It differs from whole maitake in that the biologically active glucan component is concentrated and isolated from the rest of the mushroom tissue. Hiroshi Nanba identified it as the most biologically active fraction from maitake in research starting in the 1980s, and it has since been tested in a phase I/II trial at Memorial Sloan Kettering and a 2022 randomized controlled trial during chemoradiotherapy.

Can maitake mushroom help with cancer?

The most rigorous evidence comes from two clinical contexts: a 2009 phase I/II trial at MSKCC showing immunological effects in 34 breast cancer survivors (Deng et al.), and a 2022 RCT showing reduced adverse events and better quality of life in patients undergoing concurrent chemoradiotherapy compared to placebo (Hu et al.). A 165-patient non-randomized case series found regression or improvement in 58 to 68% of cases across three cancer types. Two systematic reviews describe the evidence as consistent with adjuvant immunological support but insufficient to establish direct anticancer benefit.

Is maitake safe to take with chemotherapy?

The 2009 MSKCC phase I/II trial found no dose-limiting toxicity across doses from 0.1 to 5 mg/kg twice daily in postmenopausal breast cancer survivors (Deng et al.). The 2022 RCT tested D-fraction in patients actively receiving concurrent chemoradiotherapy and found it safe and well-tolerated alongside treatment (Hu et al.). The 2009 Ulbricht systematic review flagged theoretical interactions with warfarin and blood pressure medications that have not been confirmed at clinical doses in trial populations, but the flag remains relevant for patients on those medications.

What does Memorial Sloan Kettering say about maitake and cancer?

MSKCC researchers conducted the 2009 phase I/II trial of maitake polysaccharide extract in 34 postmenopausal breast cancer survivors and published the results in Cancer Immunology, Immunotherapy (Deng et al.). The trial found a non-monotonic dose response: intermediate doses suppressed immune function while high doses enhanced it, a finding that has significant implications for how D-fraction is dosed in clinical contexts. MSKCC's published institutional monograph on maitake describes it as likely safe, with immunological effects documented in humans and insufficient evidence for direct anticancer conclusions.

What types of cancer has maitake D-fraction been studied for?

Human clinical studies have focused on breast cancer (the MSKCC phase I/II trial with 34 disease-free survivors) and head and neck cancers, specifically laryngeal and pharyngeal, in the 2022 RCT during active chemoradiotherapy. The 165-patient case series also included liver and lung cancer patients alongside breast cancer. In vitro research covers breast cancer cell lines most extensively, including triple-negative breast cancer cells, where D-fraction was shown to activate the BAK-1 proapoptotic gene and suppress cell invasiveness.

What is the evidence for maitake and cancer?

The evidence spans three tiers. In vitro studies show D-fraction induces apoptosis and suppresses invasiveness in breast cancer cell lines via BAK-1 gene activation and downstream gene modulation. Animal studies confirm NK cell activation and tumor inhibition through an IL-12-mediated cascade. Human evidence includes a 165-patient non-randomized case series, a phase I/II trial at MSKCC in 34 breast cancer survivors, and a 2022 RCT in chemoradiotherapy patients showing fewer adverse events and preserved quality of life compared to placebo. A 2023 systematic review of all mushroom polysaccharide RCTs positioned this class of compounds as adjuvant therapy with immunomodulatory and quality-of-life benefits, with insufficient evidence for direct anticancer activity.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4RTHM-00095·Kodama, Noriko et al. (2002). “Can maitake MD-fraction aid cancer patients?.” Alternative medicine review : a journal of clinical therapeutic.Study breakdown →PubMed →↩
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.
8. 8. Source details for this reference are not yet available.
9. 9. Source details for this reference are not yet available.
10. 10. Source details for this reference are not yet available.
11. 11. Source details for this reference are not yet available.
12. 12. Source details for this reference are not yet available.